
Opinion|Videos|September 26, 2024
Recent Updates: REACH3, ROCKstar, and RWD
Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.
Advertisement
Video content above is prompted by the following:
- Briefly discuss recent updates presented at ASH 2023 and TANDEM 2024:
- 3-year analysis of REACH3, ASH 2023
- 3-year follow-up of the ROCKstar study, TANDEM 2024
- Brie fly discuss available real-world data (RWD) with ruxolitinib (Spałek A, et al. Pol Arch Intern Med. 2023) and ibrutinib (Chin KK, et al. Transplant Cell Ther. 2021;White J, et al. Transplant Cell Ther. 2023).
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


